NC410

News alerts, weekly reports and conference planners

Company:

NextCure

Drug class:

Cytotoxic T lymphocyte stimulant, Dendritic cell activator, LAIR1 antagonist

Related drugs:

‹

›

10d

KEYNOTE-D88: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)

P1/2, N=97, Active, not recruiting, NextCure, Inc. | Recruiting --> Active, not recruiting | N=209 --> 97

10 days ago

Enrollment closed • Enrollment change • Checkpoint inhibition • Metastases

MSI (Microsatellite instability)

Keytruda (pembrolizumab) • NC410

5ms

KEYNOTE-D88: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)

P1/2, N=209, Recruiting, NextCure, Inc. | N=131 --> 209

5 months ago

Enrollment change • Checkpoint inhibition • Metastases

MSI (Microsatellite instability)

Keytruda (pembrolizumab) • NC410

10ms

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)

P1/2, N=131, Recruiting, NextCure, Inc. | Phase classification: P1b/2 --> P1/2

10 months ago

Phase classification

MSI (Microsatellite instability)

Keytruda (pembrolizumab) • NC410

11ms

Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice. (PubMed, Cancer Immunol Immunother)

However, combined targeting of LAIR-1 and PD-L1 results in increased tumour control. Thus, additional targeting of the LAIR-1:collagen pathway with NC410 is a promising approach to treating tumours where conventional immunotherapy is ineffective.

11 months ago

Preclinical • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)

LAIR1 expression

NC410